Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys.

Journal Article

Accumulating evidence has demonstrated the importance of cytotoxic T lymphocytes (CTLs) and helper T lymphocytes in controlling HIV-1 replication. We have elicited immune responses in rhesus monkeys utilizing DNA vaccines augmented by the administration of IL-2/Ig, a fusion protein consisting of interleukin-2 and the Fc portion of IgG2. These vaccine-elicited immune responses did not prevent infection following a high-dose intravenous challenge with SHIV(89.6P) but did control viremia to nearly undetectable levels and prevented immunodeficiency and clinical disease. In contrast, control monkeys developed high levels of viremia and exhibited a rapid loss of CD4(+) T cells, significant clinical disease progression, and death in half of the animals by day 140 following challenge. Vaccine approaches that elicit immune responses capable of reducing plasma viral loads, but not capable of inducing sterilizing immunity, may still provide substantial clinical benefits.

Full Text

Duke Authors

Cited Authors

  • Barouch, DH; Fu, TM; Montefiori, DC; Lewis, MG; Shiver, JW; Letvin, NL

Published Date

  • November 1, 2001

Published In

Volume / Issue

  • 79 / 1-2

Start / End Page

  • 57 - 61

PubMed ID

  • 11595290

International Standard Serial Number (ISSN)

  • 0165-2478

Language

  • eng

Conference Location

  • Netherlands